Crayon

Crayon Therapeutics is a pre-clinical stage biotechnology company focused on developing a new class of "multimodal" small molecule therapeutics. The company's proprietary platform identifies single molecules capable of modulating multiple biological pathways simultaneously to treat complex diseases like cancer and neurodegeneration. By targeting fundamental processes such as mitophagy and protein homeostasis, Crayon aims to create more effective treatments for age-related conditions that have traditionally been difficult to address with single-target drugs. Headquartered in Tel Aviv, the company is supported by prominent life science investors including M Ventures and Longevity Vision Fund. Their approach seeks to overcome the limitations of traditional drug discovery by addressing the inherent complexity of multifactorial disease networks.